E
Galecto, Inc. GLTO
$3.01 -$0.03-0.99% NASDAQ
Recommendation
Prev Close
$3.04
Volume
2,394
Avg Vol (90D)
179,067
Market Cap
$4.02M
Dividend & Yield
--
52-Week Range
$2.01 - $18.50
P/E (TTM)
--
EPS (TTM)
-$18.57
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Galecto, Inc. Focuses on Oncology and Liver Diseases
4/4/2025 - TipRanks Financial Blog
Short Interest in Galecto, Inc. (NASDAQ:GLTO) Rises By 51.4%
4/1/2025 - Ticker Report
Galecto trading resumes
3/25/2025 - The Fly
Galecto trading halted, volatility trading pause
3/25/2025 - The Fly
Galecto Reports Full-Year 2024 Financial Results
3/19/2025 - GuruFocus
Galecto GAAP EPS of -$18.53 misses by $2.62
3/19/2025 - SeekingAlpha.com: All News
Galecto Reports Full-Year 2024 Financial Results
3/19/2025 - Globe Newswire
Galecto to Participate in Upcoming Investor Conferences
2/6/2025 - GuruFocus
Galecto to Participate in Upcoming Investor Conferences
2/6/2025 - Globe Newswire
Galecto (NASDAQ:GLTO) Pasithea Therapeutics (NASDAQ:KTTA) Financial Analysis
1/13/2025 - Ticker Report
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11/14/2024 - Zacks Investment Research
Galecto, Inc.'s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities
11/2/2024 - TipRanks Financial Blog
Galecto, Inc. Announces Strategic Shift and Financial Overview
11/2/2024 - TipRanks Financial Blog
Galecto reports Q3 results
11/1/2024 - SeekingAlpha.com: All News
Galecto reports Q3 EPS ($3.39) vs ($7.50)
11/1/2024 - The Fly
Galecto Reports Third Quarter 2024 Financial Results
11/1/2024 - Globe Newswire
Galecto (NASDAQ:GLTO) Price Target Increased to $10.00 by Analysts at Oppenheimer
10/17/2024 - MarketBeat - AP News
Galecto price target raised to $10 from $9 at Oppenheimer
10/17/2024 - TipRanks Financial Blog
Galecto price target raised by $1 at Oppenheimer, here's why
10/17/2024 - The Fly
Galecto announces the appointment of Wechsler to its Board of Directors
10/15/2024 - The Fly
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
10/15/2024 - Globe Newswire
Galecto buys leukemia drug from Bridge Medicines, drops bone cancer asset in strategic pivot
10/7/2024 - FierceBiotech.com - Biotech
Galecto completes strategic review, will focus on oncology, liver disease
10/7/2024 - TipRanks Financial Blog
Galecto plans to file IND for BRM-1420 in late 2025/early 2026
10/7/2024 - TipRanks Financial Blog
Galecto determines not to further advance GB2064
10/7/2024 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$16.88M
EBIT (TTM)
-$16.90M
Net Income (TTM)
-$21.44M
Balance Sheet
Total Assets (Q)
$17.13M
Total Debt (Q)
$73.00K
Total Liabilities (Q)
$1.30M
Book Value Per Share (Q)
$10.99
Cash Flow
Cash from Operations (TTM)
-$18.62M
Cash from Investing (TTM)
$11.65M
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
-$7.29M
Filings
Filing Date
Wednesday, March 19, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
End of April (est)
Price History
Loading...
Beta
2.03
7-Day Total Return
3.79%
30-Day Total Return
-55.07%
60-Day Total Return
-33.85%
90-Day Total Return
-36.24%
Year to Date Total Return
-47.19%
1-Year Total Return
-83.04%
2-Year Total Return
-94.10%
3-Year Total Return
-92.03%
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $2.01
52-week High
May 07, 2024 - $18.50
Valuation
Market Cap
$4.02M - Nano Cap
Enterprise Value
-$8.72M
Price/Sales (TTM)
--
Price/Book (Q)
0.28
Dividends and Shares
Shares Outstanding
1.31M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
galecto.com
Phone Number
45 70 70 52 10
Address
Ole Maaloes Vej 3
Copenhagen, 2200
Country
Denmark
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226... more
NASDAQ 05/06/2025 10:58AM Eastern Quotes delayed